Reuters logo
BRIEF-Pharnext completes patient enrollment in Pivotal Phase 3 trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1a
December 20, 2016 / 7:08 AM / 9 months ago

BRIEF-Pharnext completes patient enrollment in Pivotal Phase 3 trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1a

Dec 20 (Reuters) - Pharnext Sas :

* Pharnext completes patient enrollment in international pivotal phase 3 trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1a

* Results of PLEO-CMT trial are expected in second half of 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below